U.S. Markets closed
  • Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cubelast month

    Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Æterna Zentaris, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Æterna Zentaris, Inc. – Spectrum Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Bristol-Myers Squibb Company, Sanofi Sponsored ADR, Novartis AG Sponsored ADR, Halozyme Therapeutics, Inc. and Theratechnologies Inc. (SPPI-US, KERX-US, ... Read more (Read more...)

  • Associated Press2 months ago

    Aeterna Zentaris reports 2Q loss

    The Montreal-based company said it had a loss of 18 cents per share. Losses, adjusted for non-recurring gains, were 46 cents per share. The drug developer posted revenue of $243,000 in the period. In the ...

  • SmarterAnalyst2 months ago

    AEterna Zentaris Inc. (USA) (AEZS) CEO’s Departure Raises Questions

    AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are tumbling nearly 7% in Monday's trading session, following the news that CEO David Dodd is stepping down and will be succeed by Michael Ward. Most recently, Ward served as Chief Compliance & Legal Officer and Corporate Secretary for Sagent Pharmaceuticals and led its sale to Nichi-Iko Pharmaceutical for $736 million. If David Dodd turned around AEZS, why is he out?